HEPATOCELLULAR CARCINOMA

This study looked at whether giving radiation to a few growing spots of liver cancer can delay the need for stronger second-line drugs. It involved 36 adults with advanced liver cancer who had limited new tumor growth while on first-line treatment. The goal was to see if this app…

This study tested a combination of two drugs, IBI310 and sintilimab, against the standard drug sorafenib in 344 people with advanced liver cancer who had not received prior treatment. The goal was to see if the combo could help patients live longer and shrink tumors. Participants…

This study looked at how safe the drug cabozantinib is for people with advanced liver cancer (hepatocellular carcinoma) who have already tried another treatment called sorafenib. A total of 110 adults took part. The main goal was to track survival and any side effects that requir…

This study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy given directly into the liver artery for 30 people with advanced liver cancer that had spread into the main portal vein. The goal was to see if this approach could help patients live longer and…

This study tested a combination of three treatments for people with intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), drugs that help the immune system fight cancer (PD-1/PD-L1 inhibitors), and drugs that stop blood vessel growth (VEGF-TKI o…

This study looked at 74 people with liver cancer that could not be removed at first. After they had a complete response to non-surgical treatments like chemoembolization, targeted therapy, and immunotherapy, researchers compared two approaches: surgery to remove any remaining tum…

This study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This study tested whether a drug called somatostatin can prevent fluid buildup in the belly after liver cancer surgery. About 179 patients took part. The goal was to see if the drug lowers the risk of complications and shortens hospital stays.

This study tested if new, interferon-free drugs can cure hepatitis C in 150 adults who already had liver cancer treated successfully. The main goal was to see if the virus was gone 12 weeks after treatment. Researchers also watched for any signs of cancer returning.

This study tested a three-drug approach for people with advanced liver cancer that has spread into the main blood vessel of the liver (portal vein). The treatment combines chemotherapy given directly into the liver artery with two oral drugs (lenvatinib and a PD-1 inhibitor). The…

This study tested a combination of two drugs—telatinib and Keytruda—in 16 people with advanced stomach or liver cancer that had not responded to prior treatments. The goal was to see if the combo could slow cancer growth or improve survival. Participants received both drugs and w…

This study tested whether the drug pembrolizumab (an immunotherapy that helps the immune system fight cancer) could prevent liver cancer from returning in people who had already been successfully treated with surgery or ablation. About 959 participants who had no signs of cancer …

This study tested a precise, high-dose radiation treatment (CyberKnife) for people with a single liver tumor who could not have standard therapies. 44 adults received three radiation sessions over 8-10 days. The main goal was to see how many patients had no tumor growth 18 months…

This study tested a new way to make radiation therapy more effective for liver cancer. Doctors used ultrasound to pop tiny gas-filled bubbles near the tumor, which may make cancer cells more sensitive to radiation. The study involved 104 adults with liver cancer who were already …

This study tested a combination of chemotherapy infused into the liver artery, plus two immunotherapy drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be removed by surgery. The goal was to shrink the tumors enough to allow complete surgical removal…

This early-phase study tested whether combining two drugs (donafinib and an anti-PD-1 antibody) can safely prevent liver cancer from returning after surgery in 30 patients at high risk of recurrence. The goal was to see if this treatment could improve the one-year recurrence-free…

This study tested a new drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. The drug targets two proteins (PD-1 and VEGF) to help the immune system fight the cancer and cut off its blood supply. The main goals were to see if the drug is…

This study tested whether combining two procedures—chemoembolization (TACE) and radiofrequency ablation (RFA)—works better than TACE alone for people with intermediate-stage liver cancer. 241 adults with 2 to 10 liver tumors took part. The goal was to see if the combo could delay…

This study tested an improved heat-based treatment (radiofrequency ablation) for liver cancer that came back after a standard procedure. 100 adults with one to three small tumors received the treatment using special twin electrodes. The goal was to see how well the new method con…

This small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors or slow cancer growth. The study is complete, but re…

This study tested a new treatment for advanced liver cancer that has spread into the main blood vessels of the liver. 63 patients received proton beam radiation to the tumor, followed by a combination of atezolizumab (immunotherapy) and bevacizumab (targeted therapy). The goal wa…

This early-phase study tested a new drug called CHS-388 in 145 people with advanced solid tumors (including kidney, liver, and lung cancers) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cance…

This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (drugs that help the immune system fight cancer), and targeted therapy (drugs that attack cancer cells directly)—in 1244 people with advanced liver cancer tha…

This study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that had stopped responding to or could not tolerate prior treatment. The goal was to see if the combo could shrink tumors and how…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (stomach cancer, liver cancer, or other types) that had stopped responding to standard treatments. The drug was given by IV every two weeks for up to 12 doses, with the option to continue if pa…

This study tested a new way to treat small liver cancer using microwave ablation with two antennas at once, instead of the usual single antenna. Twenty adults with early-stage liver cancer took part. The goal was to see if the two-antenna method could completely destroy tumors wi…

This study tested a combination of two immunotherapy drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but had already tried other treatments. The goal was to see if the combination could shrink tumors and control …

This study tested a new treatment for people with advanced liver cancer that has spread into the major blood vessels of the liver. The treatment combines a special type of radiation (moderate-dose hypofractionated radiotherapy) with an immunotherapy drug called tislelizumab. The …

This study tested two immunotherapy drugs, nivolumab and ipilimumab, alone or together, in 657 adults with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. Participants received different…

This study looked at a flexible dosing method for delivering tiny radioactive beads (Y90 SIR-Spheres) directly to liver tumors that cannot be surgically removed. The goal was to see how well this approach controls the cancer and affects survival. Only one person took part, so res…

This study tested whether adding a new drug called SRF388 to standard treatment (atezolizumab and bevacizumab) helps people with advanced liver cancer live longer without their cancer growing. Thirty adults who had not received prior treatment for their advanced liver cancer took…

This study tested two chemotherapy drugs, cisplatin and mitomycin-C, given directly into the liver artery for people with liver cancer that cannot be surgically removed. The goal was to see how long it takes for tumors to grow and to monitor side effects. The study also looked at…

This study tested a new PET imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if the scan could accurately find cancer cells by targeting a protein called FAP. …

This study tested whether a special radioactive tracer called 68Ga-PSMA, used with PET/MRI or PET/CT scans, can find liver cancer earlier and more accurately than standard scans. Researchers enrolled 52 people with liver cancer to compare the new imaging method with usual care. T…

This study looked at whether a breath test can help find liver diseases like scarring (fibrosis), severe scarring (cirrhosis), and liver cancer early. Researchers collected breath samples from 56 adults with known or suspected liver problems. They used special machines to analyze…

This study looked at whether measuring specific microRNAs in the blood can help diagnose liver cancer in people with hepatitis C. Researchers tested 84 participants, including healthy controls and patients with hepatitis C, cirrhosis, or liver cancer. They measured levels of five…

This study looked at a new way to perform a standard liver cancer treatment called chemoembolization (TACE). Instead of going through an artery in the groin, doctors used an artery in the wrist. The goal was to see if this approach is safe, works well, and causes fewer side effec…

This study collected information on the EchoTip AcuCore, a needle used to take tissue samples during an endoscopic ultrasound. The goal was to see how often the needle successfully gets a sample without needing a replacement. The study included 183 adults with various tumors or p…

This study analyzed data from over 19,000 liver cancer patients to see if the risk of cancer spreading (metastasis) differs between men and women. Researchers used machine learning to create separate prediction models for each sex. The goal was to improve early detection and pers…

This study examined tumor and blood samples from 166 people with advanced liver cancer who received a combination of two drugs (atezolizumab and bevacizumab). The goal was to find genetic markers that could predict how well someone responds to treatment and how long they survive.…

This study enrolled 17 adults with liver cancer who were already scheduled for standard treatments like TACE or ablation. Researchers took blood samples before and after treatment to look for protein markers that might predict survival and tumor response. No experimental treatmen…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…

This study reviewed medical records of 300 liver cancer patients in Brazil to understand their health, treatments, and survival. It did not test any new drugs or treatments. The goal was to learn more about how liver cancer is managed in real-world settings.

This study looked at how well a combination of two drugs (Atezolizumab and Bevacizumab) works compared to standard pills (tyrosine kinase inhibitors) in 38 patients with liver cancer and cirrhosis. The goal was to see if the combo is safe and effective in everyday medical practic…

This study looked at the genetic makeup of liver cancer in 808 patients. The goal was to find common gene changes and patterns that could help doctors better understand the disease. Researchers used tumor samples from patients who had surgery or other treatments. The results may …